What to Expect in Month 2 Peak nausea: Weeks 6-8 worst for most patients, especially mornings Food aversions: Foods you loved suddenly repulsive (especially meat, coffee) Early satiety: Feel full after 3-4 bites, physical discomfort if you push it Fatigue increases: Combination of medication adjustment and reduced calorie intake Bowel unpredictability: Constipation one day, diarrhea the next Mental fog: Some patients report difficulty concentrating Research from the New England Journal of Medicine on incretin therapies shows this peak-and-resolution pattern is universal across GLP-1 and GIP agonists
Do not use sterile water for injections (SWI), saline, or tap water BAC water's preservative gives your reconstituted vial a 28-day shelf life Insulin syringes (U-100, 1 mL) for drawing your doses
Compound identity at a glance Name: Retatrutide INN: LY3437943 Class: Triple incretin receptor agonist Structure: 39-amino-acid synthetic peptide Dosing interval: Once weekly (research protocols) Developer: Eli Lilly For the full molecular reference (molecular formula, molecular weight, CAS number and the 39-amino-acid sequence) see the Retatrutide molecular profile
For additional guidance, refer to the FY2026 ICD-10-CM Official Guidelines, the AHA Coding Clinic, and the Amputee Coalition Healthcare Professional Resources for clinical background on amputation rehabilitation
Phase 2 Type 2 Diabetes Trial A separate Phase 2 trial evaluated retatrutide in adults with type 2 diabetes
On iOS, your data is located on your device, and syncs securely to your private iCloud storage
.jpeg)
